news

  • 14 March 2018
    Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies

    Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the United States Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9914767 to the company. This patent broadly claims composition of matter for antibodies that cross-neutralize Staphylococcus aureusalpha hemolysin (Hla) and up to four additional S. aureus leukocidins targeted by ASN-1, one of the two antibodies in the company’s lead product candidate, ASN100. ASN100 is a combination of two fully human monoclonal antibodies (mAbs) that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis, including toxins that damage lung tissue and destroy human immune cells. This patent grants intellectual property protection in the United Statesthrough 2033.

    “ASN100 is a first-in-class mAb therapeutic designed to precisely disarm a clinically important pathogen without inducing antibiotic resistance, a mechanism-of-action which underpins Arsanis’ novel approach to anti-infective development,” said René Russo, chief executive officer of Arsanis. “The cross-reactive nature of the ASN100 antibodies enables them to bind and neutralize multiple S. aureus toxins simultaneously, which we believe significantly differentiates ASN100 from other development stage mAbs that neutralize only a single toxin.”

    “The USPTO granting of this important patent follows similar patents for the composition-of-matter for these cross-reactive antibodies, including patent grants issued by the European Patent Office in 2015, and by the Japan Patent Office and IP Australia in 2017,” said Michael Gray, chief operating officer and chief financial officer of Arsanis. “We plan to continue our efforts to strengthen our intellectual property portfolio for ASN100 and our other pipeline programs.”